Source: Annual Congress 2002 - Thoracic oncology: diagnosis and prognosis
Disease area: Thoracic oncology

Abstract

Background: Tumor associated antigens, produced specifically by tumor cells, are promising targets for the early diagnosis and immunotherapy. Among tumor associated antigens, MAGE(melanoma antigen), BAGE, GAGE, PRAME, NY-ESO were named as cancer/testis specific antigens since they are detected exclusively in the testis or cancer cells, including of lung cancer. In diagnosis of lung cancer, it would be a convenient method to test MAGE, if detectable easily in the sputum. This study was to investigate the expression of MAGE in the induced sputum obtained from lung cancer patients.
Methods: In 14 control patients and 30 lung cancer patients, the induced sputum was collected after inhalation of 3% saline(5 cc), delivered by nebulizer for about 5 minutes after mouth rinse and bronchodilator inhalation. The induced sputum was put in the conservative-mixed solution (guanidiniumsothiocyanate, Triton X-100). From the obtained cells, total cellular mRNA was extracted and RT PCR and nested PCR were run in 30
and 35 cycles respectively, with two different kinds of primers specially designed to detect six subtypes of MAGE DNA simultaneously.
Results: In the 14 controls, there was no expression of MAGE, but in the 30 cancer patients, MAGE was found in 24 patients (80%, p=0.001). In cancer patients, there were no differences of expression by the tissue types (squamous cell cancer 13/17, adenocarcinoma 7/9, and small cell cancer 4/4, p=0.56). Among 24 MAGE-positive patients, tumor was not visible on bronchoscopy in 11 patients (45.8%).
Conclusion: The study of MAGE in the induced sputum seems to be an useful and complementary method in the diagnosis of lung cancer. Further prospective study with more patients should be warranted.

Rating:

Share or cite this content

Citations should be made in the following way:
M. H. Jung, T. W. Jang, C. H. Ok, C. H. Jeon, J. W. Park (Busan, South Korea). Expression of MAGE in the induced sputum of lung cancer patients. Eur Respir J 2002; 20: Suppl. 38, 3722

Member's Comments

No comment yet.

Related content which might interest you: Detection of MAGE-A expression in induced sputum and bronchial lavage fluid of patients with lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 362s Year: 2003 CEA levels in the serum and induced sputum of lung cancer patients Source: Eur Respir J 2005; 26: Suppl. 49, 324s Year: 2005 Concordance of p53 and K-ras mutations in induced sputum and corresponding biopsies of patients with nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 18s Year: 2001 Expression of Her-2/neu and Bcl-2 in patients with non-small cell lung cancer Source: International Congress 2017 – Gene signatures in bronchial diseases Year: 2017 Expression analysis of miR-223 in plasma of patients with non-small cell lung cancer and other obstructive lung diseases Source: International Congress 2018 – Lung cancer: novel prognostic markers and scores Year: 2018 CD44v6 expression in tissue of patients with lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 77s Year: 2004 Gene expression profiles in non-small cell lung cancer (NSCLC) and lung tissue in smokers and non-smokers Source: Annual Congress 2009 - Hot topics in molecular pathology and functional genomics of lung cancer Year: 2009 Evaluation expression of miR-146a and miR-155 and inflammatory  cytokines in blood of non-small cell lung cancer patients Source: Virtual Congress 2021 – Biology of lung cancer: preclinical and translational research Year: 2021 p16INK4a promoter hypermethylation in tissue, blood, and sputum from non-small cell lung cancer and pulmonary inflammation Source: Eur Respir J 2006; 28: Suppl. 50, 813s Year: 2006 Induced sputum in the diagnosis of lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 299s Year: 2004 Comparison of induced and spontaneous sputum in the diagnosis of lung cancer Source: Eur Respir J 2001; 18: Suppl. 33, 64s Year: 2001 Pleural and systemic cytokine expression profiles in patients with lung cancer Source: International Congress 2018 – Lung cancer: modern therapies and beyond Year: 2018 Molecular signatures of non-small cell lung cancer (NSCLC) obtained from gene expression profiling of the benign bronchial mucosa of smokers with and without NSCLC Source: Annual Congress 2013 –Biology and molecular pathology of lung cancer Year: 2013 The expression rate of hTERT mRNA of bronchial washing in lung cancer patients Source: Eur Respir J 2006; 28: Suppl. 50, 388s Year: 2006 Non-small cell lung cancer resected molecular expression in COPD and low function pulmonary patients Source: Annual Congress 2007 - Biology, diagnosis and rare tumours in thoracic malignancies Year: 2007 The assessment of immune cells profile in blood and induced sputum in patients with COPD developing lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 674s Year: 2006 Evaluation of serum levels of Sirtuin-1 in lung cancer patients Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer Year: 2020 Choice of endogenous control for gene expression in nonsmall cell lung cancer Source: Eur Respir J 2005; 26: 1002-1008 Year: 2005 Role of EBUS-TBNA in the study of PD-L1 expression in patients with non-small cell lung cancer (NSCLC) Source: Virtual Congress 2020 – Endobronchial ultrasound: from rookie to pro Year: 2020